uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
Neurology
Advertisement
Theranica Reports 91% Precision in AI Migraine Forecasting Study
BRIDGEWATER, N.J. and CAESAREA, Israel — September 23, 2026 Theranica announced peer-reviewed results from a study evaluating its Your...
Acadia Reports Phase 2 RADIANT Results for Remlifanserin
SAN DIEGO — September 25, 2026 Acadia Pharmaceuticals Inc. announced topline Phase 2 results from the RADIANT clinical trial...
Sun Pharma Launches Taro-Methylphenidate ER for ADHD
Mumbai, India and Brampton, Ontario, Canada, September 21, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced the commercial...
Ionis Reports Positive Phase 3 Ulefnersen Results
Carlsbad, California, U.S., September 22, 2026 Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. have announced positive...
Advertisements
Kazia Advances Paxalisib in Rare Seizure Disorders
Sydney, Australia, September 21, 2026 Kazia Therapeutics Limited has announced that its development partner Sovargen Co., Ltd. has dosed...
Lisata Acquires Marea in $225M Cardioendocrine Deal
LIBERTY CORNER, N.J. — September 17, 2026 Lisata Therapeutics announced the acquisition of Marea Therapeutics, combining the companies to...
MIRA Advances Ketamir-2 Toward Phase 2a in CIPN
MIAMI, Fla. — September 17, 2026 MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral...
OncoC4 Receives FDA Fast Track for Cesalatamig
Rockville, Maryland, USA, September 16, 2026 OncoC4, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Viatris WAKIX Approved in Japan for Sleep Disorders
Tokyo, Japan, September 16, 2026 Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
Advertisement
